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A B S T R A C T
Background
Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease that develops in a limb during exercise and is relieved
with rest. Most drug treatments of IC have a limited effect in improving walking distance. Padma 28, a Tibetan herbal preparation,
has been used to treat IC, but there is debate as to whether Padma 28 produces a clinical benefit beyond the placebo effect. This is an
update of a review first published in 2013.
Objectives
To determine whether Padma 28 is effective, compared with placebo or other medications, in increasing pain-free and maximum
walking distance for patients with intermittent claudication.
Search methods
For this update the Cochrane Vascular Trials Search Co-ordinator searched the Specialised Register (September 2015), the Cochrane
Register of Studies ((CENTRAL) (2015, Issue 8)) and clinical trials databases.
Selection criteria
Randomised controlled trials of Padma 28 compared with placebo or other pharmacological treatments in people suffering from IC.
Data collection and analysis
All review authors independently assessed the selected studies and extracted the data. Risk of bias was evaluated independently by two
review authors. Depending on the data provided in the individual trials, we extracted mean or median walking distance at the end of
the trial, or change in walking distance over the course of the trial, or both. Where not provided, and whenever possible, the statistical
significance of differences in these parameters between treatment and placebo groups in individual trials was calculated. Where possible,
data were combined by meta-analysis.
Main results
No new trials were identified in the search for this review update. In total five trials involving 365 participants were included in this
review. All trials compared Padma 28 with placebo for at least 16 weeks of follow-up. Pain-free and maximum walking distances both
increased significantly in the groups treated with Padma 28, with no significant change in the placebo group. In general, the studies
presented results comparing the treatment arms before and after treatment but made no comparisons between the Padma 28 and placebo
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groups. Pooled data of maximum walking distance after treatment with Padma 28 and placebo from two studies (193 participants)
indicated a higher maximum walking distance (mean difference (MD) 95.97 m, 95% confidence interval (CI) 79.07 m to 112.88 m,
P < 0.00001, very low quality evidence) in the Padma 28 group compared with placebo. The clinical importance of these observed
changes in walking distance is unclear as no quality of life data were reported. There was no effect on ankle brachial index (ABI): change
in ABI values between baseline and six months follow upMD -0.01, 95% CI -0.07 to 0.05, 1 study, 56 participants, P = 0.72, very low
quality evidence). Mild side effects, especially gastrointestinal discomfort, tiredness and skin eruption, were reported but this outcome
was not different between the Padma 28 and placebo groups (odds ratio 1.09, 95% CI 0.42 to 2.83, four studies, 231 participants, P
= 0.86, very low quality evidence).
Authors’ conclusions
Some evidence exists from individual trials to suggest that Padma 28may be effective in increasing walking distances, at least in the short
term (four months), in people with IC. Side effects do not appear to be a problem. However, the longer term effects of treatment are
unknown and the clinical significance of the improvements in walking distance are questionable. Moreover, the quality of the evidence
is limited by the small sample size of the available trials, limited reporting of statistical analyses that compared treatment groups, and
relatively high withdrawal rates that were linked to the outcome. That is, patients were withdrawn if they failed to improve walking
distance. There was also evidence of publication bias. We therefore feel there is currently insufficient evidence to draw conclusions
regards the effectiveness of Padma 28 in the routine management of IC. Further well-designed research would be required to determine
the true effects of this herbal preparation.
P L A I N L A N G U A G E S U M M A R Y
Padma 28 for intermittent claudication
Background
Intermittent claudication (IC) is pain in the leg that occurs on exercise and is relieved by rest. It is caused by an inadequate blood supply
to the legs due to blockage of arteries. Conservative drug treatment is commonly used in an attempt to improve walking distance in
these patients. Padma 28 is a Tibetan herbal preparation used for treating intermittent claudication.
Study characteristics and key results
This review on the effects of Padma 28 includes five trials with a total of 365 participants (current until September 2015). The review
showed that Padma 28 has some beneficial effects in improving maximum and pain-free walking distance. The groups treated with
placebo did not show an improved maximum and pain-free walking distance. Unfortunately the studies reported insufficient data to
allow the comparison of the change in walking distances in the Padma 28 group with the change in walking distances in the placebo
group. Combining the data of maximum walking distance after treatment in two studies showed that there was a longer maximum
walking distance in the Padma 28 group compared with the placebo group after 16 weeks of treatment. No change in ankle brachial
pressure was observed. Mild side effects such as gastrointestinal discomfort, tiredness and skin eruption were also noted but these were
not different between the Padma 28 and placebo groups.
Quality of the evidence
Overall, the quality of the studies was low, with evidence of publication bias, small number of trials, limited reporting of the analyses
that compared treatment groups and bias due to a high percentage of withdrawals in the placebo groups because of lack of improvement
or deterioration of the overall condition. We therefore feel there is currently insufficient evidence to draw conclusions about the
effectiveness of Padma 28 in the routine management of IC. Further well-designed research would be required to determine the true
effects of this herbal preparation.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Should Padma 28 versus placebo be used for intermittent claudication?
Patient or population: people with symptomatic interm it tent claudicat ion
Setting: outpat ient sett ing
Intervention: Padma 28
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with Padma 28
Pain f ree walking dis-
tance (PFWD)
follow up: 4 months
see comment - 79
(2 RCTs)
Unable to pool data,
one of the two stud-
ies did not provide vari-
ability data. Review au-
thors deemed the lim-
ited available data in-
appropriate for imputa-
t ion
Change in max-
imum walking distance
(MWD)
follow up: 4 months
The mean change in
maximum walking dis-
tance was
- 1.4 metres
The mean change in
maximum walking dis-
tance in the Padma 28
group was 77.1 metres
more (53.41 more to
100.79 more)
- 100
(1 RCT)
⊕⊕©©
LOW 12
Final value MWD
assessed with: tread-
mill
f ollow up: 4 months
The mean f inal value
maximum walking dis-
tance was 77.05 metres
The mean f inal value
maximum walking dis-
tance in the Padma 28
group was 95.97 me-
tres more (79.07 more
to 112.88 more)
- 193
(2 RCTs)
⊕©©©
VERY LOW 134
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Adverse ef fects
follow up: 4 months
Study populat ion OR 1.09
(0.42 to 2.83)
231
(4 RCTs)
⊕©©©
VERY LOW 156
99 per 1000 107 per 1000
(44 to 237)
Moderate
52 per 1000 56 per 1000
(22 to 134)
Final value ankle
brachial index (ABI)
follow up: 4 months
The mean f inal value
ankle brachial index
was 0.73
The mean f inal value
ankle brachial index in
the Padma 28 group
was 0.01 fewer (0.11
fewer to 0.09 more)
- 56
(1 RCT)
⊕©©©
VERY LOW 127
Change in ABI
follow up: 4 months
The mean change in an-
kle brachial index was -
0.01
The mean change in an-
kle brachial index in the
Padma 28 group was 0.
01 fewer (0.07 fewer to
0.05 more)
- 56
(1 RCT)
⊕©©©
VERY LOW 127
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
ABI: Ankle brachial index; CI: Conf idence interval; M WD: Maximum walking distance; RCT: Randomised controlled trial OR: Odds rat io; WD: Walking distance
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 possible publicat ion bias as data of one study unavailable - downgraded by one level
2 one single study, unable to asses inconsistency - downgraded by one level
3 high withdrawal rate linked to the outcome that is they were withdrawn because of failing to improve WD or as a result of
deteriorat ion in overall condit ion in Smulski 1995 - downgraded by one level
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4 l im ited report ing of stat ist ical analyses that compared the PADMA 28 and placebo groups: WD af ter treatment used rather
than change in WD. Since the baseline WDs varied between the studies the use of WDs af ter treatment could have introduced
bias - downgraded by one level
5 dif ferences between studies in baseline characterist ics such as smoking: e.g. baseline smoking rates 90% in Mehlsen 1995
and Smulski 1995 but 50% in Sallon 1998 and Schräder 1985 - downgraded by one level
6 high withdrawal rate linked to the outcome that is they were withdrawn because of failing to improve WD or as a result of
deteriorat ion in overall condit ion in Sallon 1998 and Smulski 1995 - downgraded by one level
7 high withdrawal rate linked to the outcome that is they were withdrawn because of failing to improve WD or as a result of
deteriorat ion in overall condit ion in Sallon 1998 - downgraded by one level
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Peripheral arterial occlusive disease is a leading cause of morbid-
ity in older people. The prevalence of intermittent claudication
varies by age and sex. A review of nine studies found age standard-
ised prevalence rates to be consistently higher amongst men than
women (men 0.8% to 2.9% versus women 0.6% to 1.6%) (Meijer
1998). In addition, there was a clear increase in prevalence with
age, rising from 1.0% in men aged 55 to 59 years to 6.0% in men
aged 85 years and older (0.7% and 2.5% respectively for women).
Intermittent claudication (IC) presents as the occurrence of pain,
ache, cramps, or a sense of fatigue due to inadequate blood sup-
ply to locomotor muscles distal to occlusive lesions of the sup-
plying arteries. The pain tends to start after a person has walked
a certain distance. The progression of symptoms soon compels
the person to stop (Rose 1962). Intermittent claudication per se
rarely represents a life-threatening condition. However, it is as-
sociated with reduced survival due to generalised arteriosclerosis
resulting in high frequencies of heart disease and stroke (Balkau
1994; Cassar 2006; Kannel 1970). Treatment for improving IC is
usually conservative (Coffman 1991; Pittler 2005) and includes
the avoidance or treatment of risk factors such as smoking, di-
abetes, hypertension, hypercholesterolaemia, and the promotion
of physical activity (Bendermacher 2009; Gardner 1995; Watson
2008). Additionally, pharmacologic interventions are available to
treat this condition and in some cases surgery may be beneficial
(de Backer 2012; Fowkes 2008; Salhiyyah 2012).
Description of the intervention
There are many types of drugs used for routine risk factor manage-
ment in peripheral arterial disease (PAD), including antiplatelet
agents and lipid-lowering drugs to prevent cardiovascular events.
Additionally, some vasoactive drugs have been used for the treat-
ment of symptoms and to improve walking distances.
The use of dietary supplements (especially herbal remedies) has
been increasing for the treatment of IC (Melzer 2006; Pittler
2005). This review focuses on the Tibetan herbal preparation
Padma 28, based on an ancient Lamaistic formula, which was
introduced into Europe by Badmajeff (Kowalewski 1973). The
preparation consists of a mixture of 22 different, mainly herbal in-
gredients, ranging from aconite, calendula, cardamom, camphor,
and hydrated calcium sulphate to valerian components (Smulski
1994). It has been sold for about 20 years as an over-the-counter
medicine for the treatment of IC, almost exclusively in Switzer-
land where it is manufactured (Hurlimann 1992). See Appendix
1 for the full product details.
How the intervention might work
Various mechanisms of the action of Padma 28 have been pos-
tulated including lipid-lowering activity (Samochowiec 1987a;
Smulski 1994), inhibition of blood lipid oxidisability (Brunner-La
Rocca 2005), an increase in fibrinolytic activity (Winther 1994),
inhibition of platelet aggregation (Samochowiec 1987a; Smulski
1994), modulation of neutrophil derived free radicals (Matzner
1995), inhibition of lysozyme release from neutrophils (Matzner
1995), a decrease in the oxidative burst response of monocytes
(Winther 1994), inhibition of cellular response to growth factors
involved in atherosclerosis and restenosis (Navab 2004), and in-
hibition of inflammatory cytokine production (Barak 2004) and
anti-inflammatory mechanisms in the vessel wall (Exner 2006).
Why it is important to do this review
There has been considerable debate on whether Padma 28 pro-
duces a clinical benefit beyond the placebo effect. Additionally,
the lack of standardisation and the uncertain bioavailability of the
mixture have been criticised. Therefore, a review assessing the ev-
idence on the efficacy of Padma 28 for the treatment of IC is war-
ranted.
O B J E C T I V E S
To determine whether Padma 28 is effective, compared with
placebo or other medications, in increasing pain-free and maxi-
mum walking distance for patients with intermittent claudication
(IC).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomised controlled trials of Padma 28 com-
pared with placebo or other pharmacological treatments.
Types of participants
We included participants with symptomatic IC (Fontaine stage II)
(Fontaine 1954) due to atherosclerotic disease, diagnosed either
clinically or by questionnaire, and considered suitable for conser-
vative treatment.
We excluded studies of participants diagnosed as having lower
limb atherosclerosis by clinical examination or questionnaire but
who were asymptomatic, that is who did not show symptoms.
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Types of interventions
We included all types of Padma 28 regimens versus placebo or
other pharmacological treatments.
Types of outcome measures
Primary outcomes
1. Pain-free walking distance (PFWD) or the initial
claudication distance (ICD), which is the distance walked on a
treadmill before the onset of pain.
2. Maximum walking distance (MWD) or total walking
distance (TWD) or the absolute claudication distance (ACD),
which is the maximum or absolute distance walked on a
treadmill.
Secondary outcomes
1. Proportion of patients experiencing adverse events.
2. Ankle brachial index (ABI), calculated by dividing the
systolic blood pressure in the ankle by that in the arm.
Search methods for identification of studies
There was no restriction on language or publication status.
Electronic searches
For this update the Cochrane Vascular Trials Search Co-ordina-
tor (TSC) searched the Specialised Register (September 2015).
In addition the TSC searched the Cochrane Register of Stud-
ies (CRS) http://www.metaxis.com/CRSWeb/Index.asp ((CEN-
TRAL) (2015, Issue 8)). See Appendix 2 for details of the search
strategy used to search the CRS. The Specialised Register is
maintained by the TSC and is constructed from weekly elec-
tronic searches of MEDLINE, EMBASE, CINAHL, AMED,
and through handsearching relevant journals. The full list of the
databases, journals and conference proceedings which have been
searched, as well as the search strategies used are described in the
Specialised Register section of the Cochrane Vascular module in
theCochrane Library (www.cochranelibrary.com).
The following trial databases were searched by the TSC for details
of ongoing and unpublished studies (September 2015) using the
term Padma:
• World Health Organization International Clinical Trials
Registry (http://apps.who.int/trialsearch/);
• ClinicalTrials.gov (http://clinicaltrials.gov/);
• ISRCTN registry (http://www.controlled-trials.com/)
• Nederlands Trials Register (http://www.trialregister.nl/
trialreg/admin/rctsearch.asp).
Searching other resources
For the original review version published in 2013 we contacted
one pharmaceutical company producing Padma 28 (Padma AG,
Swizerland) for information on both unpublished and ongoing
trials. The company was unwilling to release data for this review
and referred to a prior meta-analysis using unpublished data by
Melzer 2006. We were unable to obtain any additional data from
the authors of this meta-analysis.
Data collection and analysis
Selection of studies
All review authors (JM, HM, MS) independently examined the
studies identified by the search strategy for eligibility for inclusion
in the review.
Data extraction and management
All review authors (JM, HM, MS) independently extracted data
using a standard data extraction form designed by Cochrane Vas-
cular. The information extracted included: study design, method
of allocation and concealment, degree of blinding, power calcu-
lation, exclusion post-randomisation, number of withdrawals and
reasons, country where the study was undertaken, setting, par-
ticipant numbers, age and sex, inclusion and exclusion criteria,
interventions, duration of the study, and primary and secondary
outcomes as defined in Types of outcome measures.
Disagreements were resolved by discussion.
Assessment of risk of bias in included studies
Two review authors (JM, MS) independently assessed the sources
of systematic bias of the included studies according to the guide-
lines in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011). Any disagreements were resolved by discus-
sion.
We examined five key domains as part of the Cochrane ’Risk of
bias’ tool: selection bias, performance bias. attrition bias, detection
bias, and reporting bias. We assessed and classified these domains
as either a low risk of bias or a high risk of bias. Where insufficient
detail was reported in a study to assess the risk we reported this
as ’unclear’. In addition to the five key domains, we reported any
other form of potential bias noted in the study.
Measures of treatment effect
Weperformed statistical analyses according to the statistical guide-
lines for review authors by Cochrane Vascular. We analysed
the data using the Review Manager 5 software distributed by
Cochrane.
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We summarised the continuous primary outcome measures
PFWD and MWD using metres as the main unit for walking dis-
tance. If only time to onset of claudication symptoms or walking
cessation was provided, we converted it to walking distance in me-
tres by multiplying the speed of the treadmill (metres per second)
by the walking time (seconds). We reported both final walking
distance data and change in walking distance data between base-
line and follow-up where available.
For the continuous data, we extracted the mean and standard
deviation (SD) values where available. Investigation determined
that two of the studies that stated that their results were median
values were in fact reporting mean values (Samochowiec 1987;
Smulski 1995). Where standard errors (SE) were reported (Sallon
1998), we calculated the SD using the agreed formula SD = SE x√
N (Higgins 2011).
For the dichotomous secondary outcome relating to experiencing
adverse effects we reported the odds ratio (OR) and 95% confi-
dence interval (CI). The secondary outcome ABI was measured as
a continuous variable. We reported both final values and change
in ABI data between baseline and follow-up where available.
Unit of analysis issues
The individual participant was the unit of analysis.
Dealing with missing data
Where data were missing we attempted to contact the original
investigator and requested the missing data, however these were
not available.
Where outcome variables were not reported we analysed the avail-
able data. For missing data related to loss to follow-up we assumed
the data to be missing at random.
Since the validity of the study would be affected by whether
the characteristics of those participants with missing data were
reported and whether any bias was likely to have occurred, we
presented information on missing data for each study in the
Characteristics of included studies table. We considered the po-
tential impact of missing data when making the final conclusions.
In studies where medians and interquartile ranges (IQRs) were
presented and and any skewing was deemed minor from the pre-
sented outcome data, themedian was assumed to be themean and
the SD was imputed according to chapter 7.7.3.5 of the Cochrane
Handbook for Systematic Reviews for Interventions (Higgins 2011).
Assessment of heterogeneity
We explored clinical heterogeneity in the studies using the previ-
ously identified characteristics of the studies and the quality of the
included studies. We used the Chi2 test to test for heterogeneity
where data were pooled. A P value of < 0.10 was deemed to indi-
cate heterogeneity.
Assessment of reporting biases
Reporting biases commonly arise when the nature and direction
of research findings are unexpected. When contacting the phar-
maceutical company, we obtained a meta-analysis for Padma 28
(Melzer 2006) andone unpublished trial was detected in thismeta-
analysis. The results of most trials in this meta-analysis showed a
positive effect on walking distance whereas, according to Melzer
2006’s description, the unpublished study showed a non-signifi-
cant difference between treatments. We did not draw funnel plots
according to the guidelines in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011) because there were not
enough trials included in the review to give a meaningful result.
Data synthesis
Wheremeta-analyses were possible, data were pooled using a fixed-
effect model. Where it was not possible to pool the data, we re-
ported the data as presented by the studies.
Subgroup analysis and investigation of heterogeneity
We did not plan to perform subgroup analysis in this review.
Sensitivity analysis
Sensitivity analyseswere performed,where possible, using imputed
or converted median final values of walking distance and ABI. If
in future updates sufficient studies are included, we will perform a
sensitivity analysis to assess the impact ofmethodological quality of
the studies by excluding studies with low methodological quality.
Summary of findings
We created a ’Summary
of findings’ table according to Higgins 2011 and GRADE (Atkins
2004). We used the GRADEpro (GRADEproGDT) software (
http://www.guidelinedevelopment.org/) to assist in the prepara-
tion of the ’Summary of findings’ table.
We reported the following outcomes in the ’Summary of findings’
table:
• PFWD
• MWD
• adverse events
• ABI
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
Nonew studies were identified in the search for this review update.
Themethods described above therefore reflect the work carried out
for the original version of this review published in 2013, except for
the creation of the ’Summary of findings’ table which was newly
added to this version of the review.
Included studies
Type of studies
There were 12 reports to five studies included in this review
(Mehlsen 1995; Sallon 1998; Samochowiec 1987; Schräder 1985;
Smulski 1995). All were reported as randomised controlled, dou-
ble-blinded studies. The trials were carried out in hospitals inDen-
mark, Germany, Poland, and Israel.
Type of participants
For the five studies a total of 331 participants were included. Three
hundred and sixty-five participants were randomised in the stud-
ies with 34 subsequently withdrawing or being lost to follow-up.
Data were not available to allow last observation carried forward
(LOCF) analysis to be carried out. The numbers in each study
were as follows (number completing study/number commencing
study): Mehlsen 1995 36/40; Sallon 1998 59/72; Samochowiec
1987 100/100; Schräder 1985 43/53; and Smulski 1995 93/100.
The trials were published between 1985 and 1998.
Diagnosis of IC was confirmed in all participants by interview for
a typical IC history and objective clinical examination. Clinical
examination methods varied between the studies, including: ABI
(Mehlsen 1995), objective criteria for peripheral arterial occlusive
disease Fontaine stage II (Samochowiec 1987; Schräder 1985), or
conventional angiography and Doppler ultrasound (Sallon 1998;
Smulski 1995).
The distribution of participants’ age (mean or median values 54 to
73 years) and sex (men 53% to 77%) were broadly similar in the
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five studies. Whether the participants were smokers was indicated
in four trials (Mehlsen 1995; Sallon 1998; Schräder 1985; Smulski
1995) with varied proportions: approximately 50% in Schräder
1985 and Sallon 1998 and approximately 90% in Mehlsen 1995
and Smulski 1995. Co-morbidities, surgical history, medication
history, and location of peripheral arterial obstruction were similar
amongst all five studies.
The baseline maximum walking distance (MWD) differed be-
tween studies (150 m to 300 m) although the pain-free walking
distances (PFWD) were comparable. Otherwise, the conditions
for inclusion and exclusion were similar.
Type of interventions
All five trials compared Padma 28 with a placebo. There was no
comparison of Padma 28 with other medications. The dose of
Padma 28 provided to the treatment groups in the trials varied
between 340 mg and 403 mg per capsule with a total daily dose of
between 1360 mg and 2280 mg. All of the studies had a treatment
period of 16 weeks or four months with the exception of Sallon
1998 which lasted six months.
Outcomes
MWD was measured in four trials during a four-month or
16-week period of treatment with follow-up assessments every
four weeks (Mehlsen 1995; Samochowiec 1987; Schräder 1985;
Smulski 1995). Of these four studies, two also investigated PFWD
(Mehlsen 1995; Schräder 1985). For the walking test, the studies
used a treadmill with a standard intensity (3 km/hour at 13 º as
slope) with the exception of one study (Mehlsen 1995), which
used a variable condition (2.5 to 4 km/hour and 8 º to 16 º slope).
All five studies reported on the adverse effects of treatment with
Padma 28. Smulski 1995 and Mehlsen 1995 found no adverse ef-
fects. Samochowiec 1987 did not report numbers of adverse effects
or numbers of participants affected by adverse effects. However,
Samochowiec 1987 did report that all side effects were mild in na-
ture, that none required special treatment, and that no participants
stoppedbecause of adverse effects. In addition, Samochowiec 1987
stated that there was no significant difference between the treat-
ment groups in reported adverse effects. The number of partici-
pants experiencing an adverse effect was reported in Sallon 1998
(numbers of each adverse effect) and Schräder 1985 (total number
of any adverse events). Only Sallon 1998 compared the prevalence
of adverse effects between the treatment and placebo group.
ABI was investigated by Mehlsen and Sallon (Mehlsen 1995;
Sallon 1998). The ABI was obtained at baseline and the end of
treatment in both trials and not during follow-up. Schräder 1985
measured blood pressure in the upper arm and ankle at rest and
after exercise, both before and after treatment. However, the blood
pressure measures were reported as differences in blood pressure
at rest and after exercise. Therefore, ABI values could not be ex-
tracted.
For full details of the included studies see Characteristics of
included studies.
Excluded studies
One trial was excluded from this review. This trial explored the
efficacy of Padma 28 for peripheral arterial occlusive disease and
was a controlled clinical trial but was not randomised (Hurlimann
1978).
See also Characteristics of excluded studies.
Risk of bias in included studies
All five included trials were reported as randomised, controlled
double-blinded trials. Some trials did not report the method of
randomisation (Samochowiec 1987) or blinding (Samochowiec
1987; Schräder 1985). Only one trial presented a power calcu-
lation (Mehlsen 1995). Intention-to-treat analyses were not per-
formed in the included trials with the exception of Samochowiec
1987 in which all participants completed the study.
Full details of each of the domains in the ’Risk of bias’ tool are given
below and summarised in Figure 2, Figure 3, and Characteristics
of included studies.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
For Mehlsen 1995; Sallon 1998; Schräder 1985; Smulski 1995,
the allocation sequence was generated by random numbers, per-
mutation list or automated computer lists. Samochowiec 1987 did
not report on allocation generation and concealment.
For Mehlsen 1995 and Smulski 1995, in order to conceal the
identity of the interventions from both the participants and inves-
tigation team, Padma 28 and placebo were identically packaged
by the manufacturer, coded, and then handed over to the study
teams. Although reported in less detail, Sallon 1998; Samochowiec
1987; and Schräder 1985 appear to have used a similar process of
concealment (stating the identical appearance of Padma 28 and
placebo and that each had a code on its packaging).
Blinding
Mehlsen 1995 and Smulski 1995 reported that the investiga-
tion team, outcome assessors, and participants in the study were
blinded while conducting the study. Both Padma 28 and the
placebo were identically packaged and coded. The drugs were pro-
duced by the manufacturer as capsules that were identical in ap-
pearance, taste, and packaging. The randomisation schedule was
kept hidden until after the completion of data collection. Sallon
1998 reported that participants and staff were blinded, with no
additional details. While both Samochowiec 1987 and Schräder
1985 were reported to be double-blinded trials, the authors did
not provide further details of blinding.
Incomplete outcome data
Please see Table 1 for details.
There were no withdrawals from Samochowiec 1987. Mehlsen
1995 reported that four participants, two in the treatment group
and two in the placebo group,were excludedwithin the firstmonth
because of insufficient time to attend the study or due to non-
attendance. These exclusions were not related to clinical factors.
Sallon 1998; Schräder 1985; and Smulski 1995 provided detailed
explanations of the withdrawals from their studies. Numbers of
withdrawals were equal between the treatments groups for Sallon
1998 and Schräder 1985 but a larger number of withdrawals was
shown by Smulski 1995 in the placebo group. Generally, the time
points of withdrawals in Sallon 1998; Schräder 1985; and Smulski
1995 were described as before the end of the study period.
In total, one patient in the Padma group (Sallon 1998) and four
participants in the placebo groups (three from Sallon 1998 and
one from Schräder 1985) withdrew because of no improvement in
walking distance. An additional nine participants from the placebo
groups (three from Sallon 1998 and six from Smulski 1995) with-
drew because of a deterioration in walking distance. These with-
drawals were directly related to the walking distance outcomes and
make the Sallon 1998 and Smulski 1995 trials at high risk of at-
trition bias.
Selective reporting
Mehlsen 1995; Sallon 1998; Samochowiec 1987; and Smulski
1995 reported all of the intended outcomes. The main pre-speci-
fied outcomesmeasured on the treadmill, PFWDandMWD,were
reported for Schräder 1985 but one additional outcome based on
subjective evaluation of effectiveness by both the physician and
the participants was not described.
Other potential sources of bias
TheMehlsen 1995 and Schräder 1985 studies stated that the base-
line characteristics of participants were not different between the
Padma 28 and placebo groups. Smulski 1995 reported that the dis-
tribution of patient characteristics was statistically random among
the control groups at the time of randomisation. Samochowiec
1987 listed some baseline characteristics but did not report on the
differences of the baseline characteristics between the Padma 28
and placebo groups. Sallon 1998 reported that the baseline charac-
teristics of participants were not significantly different. However,
confusing reports of the numbers and characteristics of evaluated
participants were found. Of a total of 72 participants at baseline
the numbers of withdrawals were 13, six from Padma 28 and seven
from the placebo group. Thus the evaluated participants were 31
in the treatment group and 28 in the placebo group. ABI was
tested on 25 participants, not 28, in the placebo groupwithout any
reason being given. Moreover, the measurement requiring exercise
on the treadmill (not an outcome in this review) was completed
in only 47 participants, 25 in the treatment group and 22 in the
placebo group, without reasons being provided.
The review authors are aware of one unpublished study (
Sommoggy 1990), as reported in a systematic review by Melzer
2006. Contact with the pharmaceutical company and the authors
of the systematic review proved unsuccessful in obtaining the re-
quired data. Melzer 2006 reported that this unpublished study
provided the only data reported as not supporting a significant
effect of Padma 28 compared with placebo. This can be seen as a
form of publication bias.
Effects of interventions
See: Summary of findings for the main comparison Padma 28
versus placebo
All five included trials compared Padma 28 with a placebo. There
was no comparison of Padma 28 with other medications.
Change in walking distance (WD) (PFWD and MWD) was the
preferred outcome for this review, especially in light of the dif-
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ferences in MWD between treatment groups at the start of the
trials. However, limited data were presented on change in mean
values, preventing a meta-analysis of the difference in change be-
tween the two treatment groups. Therefore, descriptive details of
the changes within each study group as well as the mean WD or
median WD data after treatment are presented below and in the
additional tables.
Details of the available data for each of the included studies are
presented by outcome below and in the additional tables.
Padma versus placebo
Pain-free walking distance (PFWD)
PFWD was reported in two studies (Mehlsen 1995; Schräder
1985). Both studies reported PFWD in medians, with Mehlsen
1995 reporting median baseline and follow-up PFWD with in-
terquartile ranges (IQRs) and Schräder 1985 reporting change in
median PFWDdata as well as baseline and final value PFWDdata.
It should be noted that the two studies used different intensities
of walking tests. See Characteristics of included studies for details.
In Mehlsen 1995 the median PFWD increased from 52 m (IQR
20 to 106) to 86m (IQR24 to 164) after fourmonths of treatment
in the Padma 28 group (P < 0.01), and from 70 m (IQR 29 to
140) to 71 m (IQR 29 to 120) in the placebo group (P = not
significant (NS)). The authors did not report on the change in
median PFWD between the placebo and Padma 28 groups but
changes in median PFWD were calculated by the review authors
to be 34 m (Padma 28) versus 1 m (placebo). Converting median
final PFWD values into mean PFWD values and calculating SDs
allowed a comparison between the Padma 28 and placebo groups,
showing a statistically non-significant mean difference (MD) in
PFWD of 15.00 m (95% CI -42.15 to 72.15, P = 0.61) (Analysis
2.1)
Schräder 1985 found that after 16 weeks of treatment, PFWD
increased by 66 m in the Padma 28 group (P = 0.002) compared
with 30 m in the placebo group (P = 0.01). This difference in
change in PFWD between the treatment groups was not statisti-
cally significant (P = 0.06). While data on WD at the start and
end of the trial were provided, no information on the variability
was provided therebymaking it not possible for the review authors
to pool the final value PFWD data with the Mehlsen 1995 study.
In addition, due to the limited data the review authors deemed it
inappropriate to impute SDs for changes in PFWD data and to
pool the data.
For additional details see Table 2.
Maximum walking distance (MWD)
MWD was evaluated in four trials (Mehlsen 1995; Samochowiec
1987; Schräder 1985; Smulski 1995). The final point of treatment
was 16 weeks (four months) in all trials and the intensities of the
walking tests were similar with the exception of Mehlsen 1995, as
described in Included studies.
Samochowiec 1987 and Smulski 1995 presented the outcome as a
median but, as described in Measures of treatment effect, on fur-
ther investigation it was determined that their results were in fact
mean values. Samochowiec 1987 found a statistically significant
change in MWD in the Padma 28 group with an improvement of
76m (from 80.6 m to 156.2 m, P < 0.001). The placebo group did
not show a statistically significant change in meanMWD (68.1 m
to 66.6 m, P > 0.1). The authors did not report on the difference
between the Padma 28 and placebo groups but this could be cal-
culated from the available data, showing a statistically significant
increase in MWD of 77.10 m (95% CI 53.41 to 100.79, P <
0.00001, low quality evidence) (Analysis 1.1). In Smulski 1995,
the MWD was shown to have risen significantly by 100 m in the
Padma 28 group (87.5 m to 187.7 m, P < 0.001) and by 13 m
in the placebo group (from 75.0 to 87.5 m, P = NS). Smulski
1995 did not report the SDs for change in mean MWD. The
authors did not report on the difference between the Padma 28
and placebo groups. Due to missing SDs for the mean MWD
in Smulski 1995, the change in MWD data could not be pooled
with the Samochowiec 1987 data. The review authors deemed it
was inappropriate to impute the SDs with the limited number of
studies included in this review.
The MWD data after treatment from Samochowiec 1987 and
Smulski 1995 were pooled showing a statistically significant dif-
ference in final MWD values between the Padma 28 and placebo
groups (MD 95.97 m, 95% CI 79.07 to 112.88, P < 0.00001,
very low quality evidence) (Analysis 1.2). There was no evidence
of heterogeneity (Chi2 test P = 0.055).
Mehlsen 1995 and Schräder 1985 used medians to report the out-
come measure and the results were not pooled with Samochowiec
1987 and Smulski 1995. Mehlsen 1995 detected a significant in-
crease in median MWD of 112 m in the Padma 28 group (115 to
227 m, P < 0.001) and an increase of 7 m in the placebo group
(125 to 132 m, P = NS). This study also noted differences in
effect size within the Padma 28 group with 7/18 participants at
least doubling their MWD. Three participants in the Padma 28
group reached > 500 m WD and were no longer restricted by IC
in their daily life. In comparison, only one of 18 participants in
the placebo group attained a doubling of WD distance and none
of the placebo group achieved a WD of > 500 m. The authors
did not report the difference between the Padma 28 and placebo
groups. Schräder 1985 reported an increase in the median value
of MWD by 124 m in the Padma 28 group (P < 0.01) and 27
m (P = NS) in the placebo group. The authors reported that the
increase in MWD was significantly different between the Padma
28 and placebo groups (P = 0.03).
The median MWD data after treatment fromMehlsen 1995 were
deemed too skewed to pool with the final MWD data analysis of
Samochowiec 1987 and Smulski 1995. Due to a lack of studies the
review authors deemed the imputation of SDs for Mehlsen 1995;
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Schräder 1985; and Smulski 1995 inappropriate and therefore a
sensitivity analysis of pooled change in MWD data with imputed
data was not performed.
For additional details see Table 3.
Adverse effects of therapy
In the four trials that reported data on side effects (Mehlsen 1995;
Sallon 1998; Schräder 1985; Smulski 1995), 24 out of 231 (10%)
participants reported at least one adverse effect. Adverse effects
from Padma 28 were found in two studies (Sallon 1998; Schräder
1985), with Mehlsen 1995 and Smulski 1995 reporting that there
were no adverse effects. The main adverse effects reported were
gastrointestinal discomfort, tiredness, and skin eruptions. Pooling
the adverse effects data showed there was no statistically significant
difference in adverse effects between the Padma 28 and placebo
groups (odds ratio (OR) 1.09, 95% CI 0.42 to 2.83, P = 0.86,
very low quality evidence) (Analysis 1.3). There was no evidence
of heterogeneity (Chi2 test P = 0.44). Samochowiec 1987 did not
report numbers of adverse effects or numbers of participants af-
fected by adverse effects. However, Samochowiec 1987 did report
that all side effects were mild in nature and that none required
special treatment. In addition, Samochowiec 1987 reported that
there was no significant difference between the treatment groups
and that no participants stopped treatment because of adverse ef-
fects.
See also Table 4.
Of the 34 withdrawals from the five studies, five where technical
exclusions such as poor compliance (two) and insufficient time to
participate (three); the remainder were patient withdrawals. There
were 13/184 (7%) withdrawals from the Padma 28 groups and
21/181 (12%) withdrawals from the placebo groups. From the
Padma 28 groups, 8/13 withdrawals were due to clinical concerns:
two cardiac problems, three gastrointestinal discomfort, one back
pain, one toe amputation, and one bladder carcinoma. In addi-
tion, the Padma 28 groups recorded a single death due to my-
ocardial infarction in a participant with a complex cardiovascular
history. From the placebo groups, 6/21 withdrawals were due to
clinical concerns: two cardiac problems, one stroke, one lumbago,
one dyspnoea (shortness of breath), and one gastrointestinal dis-
comfort. In total, one patient in the Padma groups and four par-
ticipants in the placebo groups withdrew because of no improve-
ment in walking distance, and nine participants from the placebo
groups withdrew because of a deterioration in walking distance.
For additional details see Table 1.
Ankle brachial index (ABI)
ABI was extracted from two studies (Mehlsen 1995; Sallon 1998).
Mehlsen 1995 reported themedian value of ABI after fourmonths
with a reduction of 0.03 in the Padma 28 group (0.62 to 0.59)
and an increase of 0.02 in the placebo group (0.59 to 0.61), with
no differences between baseline and follow-up for the two groups.
Mehlsen 1995 did not compare the two groups with each other.
Sallon 1998 reported both final ABI values and the change in
ABI values for both treatment groups. Sallon 1998 reported no
significant change in ABI after six months of treatment for both
treatment groups. Sallon 1998 did not analyse the difference be-
tween the Padma 28 and placebo groups but the data presented
for the final ABI values indicated no significant difference between
the two treatment groups for ABI values after treatment (MD -
0.01, 95% CI -0.11 to 0.09, P = 0.84, very low quality evidence)
(Analysis 1.4) and change in ABI values between baseline and at
six months (MD -0.01, 95% CI -0.07 to 0.05, P = 0.72, very low
quality evidence) (Analysis 1.5).
A sensitivity analysis was performed in order to combine the ABI
data of the Mehlsen 1995 and Sallon 1998 studies. The median
ABI data after treatment from Mehlsen 1995 were assumed to be
the mean ABI data after treatment and SDs were calculated and
pooled, showing no difference in ABI after treatment between the
Padma 28 and placebo groups (MD -0.01, 95% CI -0.10 to 0.08,
P = 0.79) (Analysis 2.2). Due to the lack of studies presenting
change in ABI data, the review authors deemed it inappropriate
to impute change in ABI data for the Mehlsen 1995 study.
For additional details see Table 5.
D I S C U S S I O N
Summary of main results
Some evidence exists from individual trials to suggest that patients
with intermittent claudication (IC) may benefit from daily Padma
28 in terms ofmoderate, short term (fourmonth) improvements in
walking distances (WDs). Neither Padma 28 nor placebo had any
statistically significant effect on ankle brachial index (ABI). Side
effects do not appear to be a problem. However, the longer term
effects of treatment are unknown and the clinical significance of
the improvements in WD are questionable. Moreover, the quality
of the evidence is limited by the small sample size of the available
trials, lack of detail on key elements required to assess other sources
of bias for example around randomisation and blinding, limited
reporting of statistical analyses that compared treatment groups,
and relatively high withdrawal rates that were linked to outcome.
That is, withdrawn if failed to improve walking distance. There
was also some evidence of publication bias.
Overall completeness and applicability of
evidence
All of the included trials were applicable to the general older pop-
ulation with IC. The participants of all studies were middle aged
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or older people (range 35 to 81 years) and were diagnosed by clin-
ical examination or questionnaire and the WDs were tested on
standardised equipment such as treadmills.
The clinical significance of the change in WDs is questionable.
Typically, the change in median PFWD reflected a doubling in
median PFWD, ranging from 1 m to 66 m between the included
studies. For change in mean or median MWD, the change in
MWDranged from -1.4m to 124mbetween the included studies.
Quality of the evidence
Overall, the included studies were of limited methodological qual-
ity. Two studies (Samochowiec 1987; Schräder 1985) did not re-
port details on participant or study personnel blinding, which
could be considered a methodological limitation. Schräder 1985
also did not report on all predefined outcomes for their study,
which was therefore considered to be at high risk of selective re-
porting bias.
Differences between the included studies in baseline participant
characteristics such as smoking status of participants (e.g. baseline
smoking rates 90% in Mehlsen 1995 and Smulski 1995 but 50%
in Sallon 1998 and Schräder 1985) may have had an impact on
the outcomes studied.
The included trials were all small and the different reporting styles
prevented pooling studies to produce a stronger result. In general,
there was limited reporting of statistical analyses that compared
the treatment groups. This resulted, in some cases, in the review
authors using WDs after treatment rather than changes in WD.
Since the baselineWDs varied between the studies the use ofWDs
after treatment could have introduced bias.
There was a high rate of withdrawals linked to the outcome. That
is they were withdrawn because of failing to improve WD or as a
result of deterioration in overall condition (Sallon 1998; Smulski
1995), introducing attrition bias.
The quality of the evidence in this review is also limited by the
review authors being unable to acquire additional information
and data to allow more formal meta-analyses of the primary or
secondary outcomes. A meta-analysis undertaken by Melzer 2006
included data from an unpublished study which we were unable
to gain access to. This omission has the potential to alter the
conclusions of the review (see Agreements and disagreements with
other studies or reviews below) and it may reflect previous negative
publication bias.
Overall the quality of the evidence according to the GRADE
principles is very low, see Summary of findings for the main
comparison.
Potential biases in the review process
This review was conducted by following the review question and
predefined protocol. Data analysis was undertaken using both nar-
rative and statistical pooling methods in accordance with the avail-
able data.
In some cases the review authors assumed that reported median
WDs were mean WDs and calculated the corresponding SDs in
order to pool the data with other studies. Such assumptions can
introduce bias especially when very few studies are available. For
this reason, these analyses were presented as sensitivity analyses.
For this reason also, the review authors deemed it inappropriate
to impute SDs of the change in WD data in order to pool the
available change in WD data.
Agreements and disagreements with other
studies or reviews
The meta-analysis conducted by Melzer 2006 evaluated evidence
on the efficacy and safety of Padma 28 in treating peripheral ar-
terial occlusive disease, Fontaine stage II. The meta-analysis was
conducted according to a pre-specified protocol, which the au-
thors reported was guided by Cochrane methodology. Their anal-
ysis identified seven trials for investigating WD and then com-
bined five of them. Five of the trials were the same studies as in
this Cochrane review. However, Sallon 1998 and Smulski 1995
were excluded from the meta-analysis by Melzer 2006 due to not
having MWDdata and because of concerns over differences in the
baseline characteristics of the two treatment groups, respectively.
The additional studies included by Melzer 2006 were an unpub-
lished controlled trial (Sommoggy 1990) and a historical re-anal-
ysed non-randomised study (Samochowiec 1987b). Melzer 2006
was able to access original data for nearly all of the studies, allowing
a meta-analysis to be undertaken. The results of Sommoggy 1990
were the only data reported as not supporting a significant effect
of Padma 28 compared with placebo. Overall, the result of the
meta-analysis by Melzer 2006 was consistent with our own, with
reporting of a significant difference in change in MWD between
the two treatment groups (MWD 63.5 m, 95% CI 27.1 to 99.9
m, P < 0.001). However, the clinical significance of this degree of
improvement can be questioned.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Some evidence exists from individual trials to suggest that patients
with intermittent claudication (IC) may benefit from daily Padma
28 in terms of moderate, short term (four month) improvements
in walking distances. Side effects do not appear to be a problem.
However, the longer term effects of treatment are unknown and
the clinical significance of the improvements in walking distance
are questionable. Moreover, the quality of the evidence is very
low, limited by the small sample size and difference in baseline
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characteristics such as smoking of the available trials, lack of detail
on key elements required to assess other sources of bias for example
around randomisation andblinding, limited reporting of statistical
analyses used to compare treatment groups, and relatively high
withdrawal rates that were linked to outcome, that is withdrawn
if failed to improve walking distance. There was also evidence of
publication bias. We therefore feel there is currently insufficient
evidence to draw conclusions regards the effectiveness of Padma
28 in the routine management of intermittent claudication.
Implications for research
Further research into Padma 28 as a treatment for IC would be
beneficial in order to formulate a definitive answer. Large method-
ologically sound trials need to be conducted. The main outcomes
of walking distance, ABI, and quality of life are needed for ade-
quate evaluation in order to identify clinically relevant changes.
Further trials in which patients are followed up over a long term
period are also needed. In addition, any future studies should en-
sure the outcomes reported include the assessment of change be-
tween the treatment groups studied.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Mehlsen 1995
Methods Study design: Randomised, double-blind, placebo-controlled trial
Method of randomisation: Random numbers
Concealment of allocation: Coding by manufacturer
Blinding: Patient and investigation team
Power calculation: Observed SD 47 m; change of parameter 55 m; ß (type II error) 90%
Number of participants randomised: 40
Number of participants analysed: 36
Number of exclusions post randomisation: 4 within the first four weeks from the study
Timing of study: Not stated
Participants Country: Denmark
Setting: Hospital
Number of centres: 1
Number of participants: Padma 28 20; Placebo 20
Median age (IQR): Padma 28 67 yrs (48 - 81 yrs); Placebo 66 yrs (44 - 77 yrs)
Sex: 19 male/17 female (Padma 28 9/9; Placebo 10/8)
Smoking: Padma 28 15/18; Placebo 17/18
Inclusion criteria: The clinical diagnosis of IC verified by typical IC history confirmed
by interview, clinical present for more than six months, MWD between 50 and 300 m
and ABI lower than 0.85
Exclusion criteria: Participants with symptoms of chronic lung disease, diabetes mellitus,
osteoarthrosis in the lower extremities, or other diseases limiting the walking distance
Interventions Treatment: Padma 28 (340 mg) two capsules twice a day
Control: Placebo
Duration: 4 months (F/U 4, 8, 12 and 16 weeks)
Outcomes 1. Bilateral systolic blood pressure at the ankle and first toe
2. Systolic blood pressure on both upper limbs
3. Walking distance: PFWD and MWD
4. ABI
Notes No intention-to-treat analyses due to dropout in the very early stage of the study
Patient not permitted to change medication or life-style during the study period
Circumstance of measurement at baseline: treadmill with an elevation 8º to 16º and 2.
5 to 4.0 km/h speed
Adverse effects investigated, none reported
Reporting of significance level: authors report results are not significant but do not
provide definition
Risk of bias
Bias Authors’ judgement Support for judgement
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Mehlsen 1995 (Continued)
Random sequence generation (selection
bias)
Low risk Reports: The participants were assigned on
the basis of random numbers
Allocation concealment (selection bias) Low risk Reports: Medication coding was under-
taken by the manufacturer; placebo and
Padma 28 were identically packaged; the
investigation team were unaware of the
coding system
Blinding (performance bias and detection
bias)
All outcomes
Low risk Reports: Double-blind methodology; the
resultswere entered prior to decoding;mea-
surements were undertaken by two nurses
who were unaware of the randomisation
process
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reports: 2/20 missing from intervention
group; 2/20 missing from control group.
Full details of attrition provided: 3/4 miss-
ing participants did not have sufficient time
to participate in the study; 1/4 did not at-
tend on the specified date
Selective reporting (reporting bias) Low risk Reports: All expected outcomes reported
Other bias Low risk Reports: The Padma28 andplacebo groups
did not differ by age, sex, smoking, surgical
history and duration of illness
Sallon 1998
Methods Study design: Randomised, double-blind, placebo-controlled trial
Method of randomisation: Computer generated
Concealment of allocation: Not stated
Blinding: Participants and investigators
Power calculation: Not stated
Number of participants randomised: 72
Number of participants analysed: 59
Number of withdrawals: 13 (6 in intervention group and 7 in placebo group)
Timing of study: June 1993 - July 1995
Participants Country: Israel
Setting: Hospital
Number of centres: 1
Number of participants: Padma 28 37; placebo 35
Mean age (± SE): Padma 28 72.4 ± 1.6 yrs; placebo 73 ± 1.6 yrs
Sex: 42 male/30 female (Padma 28 19/18; Placebo 23/12)
Smoking: Padma 28 59.5% (22/37); Placebo 45.7% (16/35)
Inclusion criteria: Abnormal wave-form recordings using bidirectional Doppler; a pre-
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Sallon 1998 (Continued)
exercise ankle-arm pressure ratio of≤ 0.85; a post-exercise drop in the ankle-armpressure
ratio ≥ 15% compared with the pre exercise ratio; a depressed systolic ankle pressure
during 3 minutes post-exercise
Exclusion criteria: Lower extremity rest pain; ulceration or need for revascularization;
previous peripheral arterial surgery; use of anticoagulant warfarin; active peptic ulcer
disease; serious liver or renal disease; mental disease; a significant or serious cardiac
condition; carcinoma and other life-threatening condition
Interventions Treatment: Padma 28 (403 mg) two capsules twice a day
Control: Placebo (potato starch) two capsules twice a day
Duration: 6 months
Outcomes 1. Resting ABI
2. Pressure drop
3. Pressure recovery time
4. Ischaemic window
Notes No intention-to-treat analysis or power calculation
Participants continued all usual medications except those affecting blood flow and pe-
ripheral blood vessels
Walking distance measurement method: 2 km/h at a 10º upward incline
Adverse events investigated: experienced by 8 participants. The numbers of each adverse
event were reported
Padma 28 supplier: Padma AG, Zollikon, Switzerland
Reporting of significance level: authors report results are not significant but do not
provide definition
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Reports: “Randomisation lists were gener-
ated by an automatic computerized proce-
dure developed to produce two balanced
groups by the capsule manufacturer at the
factory”
Allocation concealment (selection bias) Low risk Reports: “Randomisation was to either
Padma 28 or an identical-looking placebo”,
“patients and staff were blinded as to treat-
ment assignment”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Reports: “Patients and staff were blinded as
to treatment assignment”. There was no in-
formation to determine whether the blind-
ing was maintained during study
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Sallon 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Reports: Comprehensive attrition data re-
ported; 6/37 missing from intervention
group; 7/35 from placebo group. Since
six out of the seven withdrawals from the
placebo group are outcome-related (no im-
provement or deterioration in condition)
attrition bias has been coded as high risk
Selective reporting (reporting bias) Low risk Reports: All expected outcomes reported
Other bias Unclear risk Confusing reports of the numbers and
characteristics of evaluated participants
were found. Of 72 total participants at
baseline, the numbers of withdrawals were
six from Padma 28 and seven from the
placebo group. Thus the evaluated partici-
pants were 31 in the Padma 28 group and
28 in the placebo group. ABI was tested
on 25 participants, not 28, in the placebo
group without a reason being given. More-
over, the measurement requiring exercise
on the treadmill (not an outcome in this
review) was completed in only 47 partici-
pants, 25 in the Padma 28 group and 22 in
the placebo group
Authors report there were no differences
between patient characteristics at time of
randomisation
Samochowiec 1987
Methods Study design: Randomised, double-blind, placebo-controlled trial
Method of randomisation: Not stated
Concealment of allocation: Not stated
Blinding: Not stated
Power calculation: Not stated
Number of participants randomised: 100
Number of participants analysed: 100
Number of withdrawals: None
Timing of study: Not stated
Participants Country: Poland
Setting: Medical centre
Number of participants: Padma 28 55; Placebo 45
Mea age (range): Padma 28 57.5 yrs (41 - 69 yrs); Placebo 57 yrs (45 - 65 yrs)
Sex: 67 males / 33 females (Padma 28 40/15; Placebo 27/18)
Smoking: Not reported
Inclusion criteria: Diagnosis of arterial occlusive disease of Fontaine II based on clinical
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Samochowiec 1987 (Continued)
criteria; MWD < 150 m; minimum duration of IC of 8 months
Exclusion criteria: Stage other than Fontaine II; concomitant disease including - venous
disorders, anaemia, significant ill-health (e.g. myocardial infarction) within 8 months,
uncontrolled hypertension, kidney or liver insufficiency
Interventions Treatment: Padma 28 (380 mg) two capsules twice a day
Control: Placebo (Lactose 400 mg) two capsules twice a day
Duration: 16 weeks (F/U 4,8,12,16 weeks)
Outcomes 1. Blood pressure
2. MWD
3. Serum/plasma testing (biochemistry,electrolytes, liver enzymes, blood cell count)
Notes Additional study criteria: there was a preliminary period of 2 weeks
Participants were requested to stop vasoactive medication
Walkingdistancemeasurementmethod: 100mwith 3.2 km/h speed andupward gradient
from 13º
Adverse event investigation: no formal assessment of adverse effects, reports that mild
side effects did not require treatment
Additional patient information: location of the vascular obstruction Padma 28: 15 iliac,
35 femorodistal, 5 iliofemoral; Placebo: 12 iliac, 30 femorodistal, 3 iliofemoral
Reporting of significance level: authors did not specifically report on significance levels
but report P values for their comparisons
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reports: randomised methodology how-
ever the sequence generation process was
not stated
Allocation concealment (selection bias) Low risk Reports: “The patients in the study got the
medicine appropriately to their code num-
ber”, “Themedicationsweremade byman-
ufacturer, which were not outwardly differ-
ent between Padma 28 and placebo”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No information reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reports: There were no data missing
Selective reporting (reporting bias) Low risk Reports: All expected outcomes reported
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Samochowiec 1987 (Continued)
Other bias Unclear risk The characteristics of evaluated partici-
pants between both groups were not de-
scribed
Schräder 1985
Methods Study design: Randomised, double-blind, placebo-controlled trial
Method of randomisation: Random numbers
Concealment of allocation: Not stated
Blinding: Not stated
Power calculation: Not stated
Number of participants randomised: 53
Number of participants analysed: 43
Number of withdrawals: 10
Timing of study: Not stated
Participants Country: Germany
Setting: Not stated
Number of participants: Padma 28 27; placebo 26
Mean age: Padma 28 68.6 yrs; placebo 69.3 yrs
Sex: 41 male/12 female (Padma 28 21/6; placebo 20/6)
Smoking: Padma 28 11/29; placebo 12/24
Inclusion criteria: Diagnosis of PAOD in Fontaine II based on clinical criteria and non
invasive examination, MWD < 250 m, duration of illness of at least 8 months, older
than 50 years, good compliance
Exclusion criteria: Concomitant vasoactive therapy, concomitant serious diseases such
as myocardial infarct within the last 8 months, cardiac insufficiency, disease limiting
walking distance other than IC, not steady state of PAOD
Criteria for formal withdrawal from trial: intolerance of treatment; deterioration of the
PAOD (Fontaine stage III or IV); intercurrent significant ill health; change in concomi-
tant medication; change in lifestyle; lack of compliance
Interventions Treatment: Padma 28 (380 mg) two capsules three times a day
Control: Placebo (Lactose 400 mg) two capsules three times a day
Duration: 16 weeks
Outcomes 1. Ankle and upper arm blood pressure at rest and after exercise
2. PFWD and MWD
3. Subjective assessment for judging effectiveness of each intervention
4. Compliance and adverse effects
Notes Additional study criteria: there was a preliminary period of 2 weeks
No intention-to-treat analyses
Participants were requested to stop vasoactive medications but were able to continue all
other usual medications
Walkingdistancesmeasurementmethod: treadmill set at 100mwith 13º upward gradient
and 3 km/h speed
Adverse effect reporting: 16 participants experienced adverse effect. The symptoms were
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Schräder 1985 (Continued)
reported but the numbers who experienced each symptom were not reported
Reporting of significance level: Statistical significance level was reported as P < 0.05
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Reports: “The patients were distributed
randomly in the two groups”
The PVD group contacted the author in
1995 who advised that the methodology
was “random numbers”
Allocation concealment (selection bias) Low risk Reports: “The medication was coded on
packing”
Detailed information on the process of al-
location concealment was not described,
however “coding” is likely to be sufficient
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No information reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reports: Full details of attrition were re-
ported; 4/27 missing from Padma 28
group; 6/26 missing from placebo group
Selective reporting (reporting bias) High risk Reports: The study included all stated
outcomes except subjective effectiveness.
PFWD, MWD and ankle arterial BP were
given as change scores
Other bias Low risk The participants in the two groups were
considered statistically identical
Smulski 1995
Methods Study design: Randomised, double-blind, placebo-controlled trial
Method of randomisation: The Rumke and de Jong permutation list
Concealment of allocation: Encoded sealed packages
Blinding: Participants and examining/treating physician
Power calculation: Not stated
Number of participants randomised: 100
Number of participants analysed: 93
Number of withdrawals: 7
Timing of study: May 1984 - June 1989
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Smulski 1995 (Continued)
Participants Country: Poland
Setting: Hospital
Number of participants: Padma 28 50; Placebo 50
Mean age: Padma 28 58 yrs; Placebo 54 yrs
Sex: 60 males/40 females (Padma 28 30/20; Placebo 30/20)
Smoking: Padma 28 47/50; Placebo 46/50
Inclusion criteria: Written agreement by the patient to participate in the study; Fontaine
II; positive history of typical IC with walking distance until onset of calf pain; missing
or deficient pulse on back of foot; MWD < 250 m; minimum 6 month duration of IC;
good compliance and availability for follow-up
Exclusion criteria: PAOD other than Fontaine II concomitant severe diseases or disease
impeding walking ability; deficient steady state of PAOD II
Criteria for formal withdrawal from trial: Intercurrent severe illness; changes in lifestyle;
changes in medication therapy for concomitant disease; intolerance to administered
medication; poor compliance; failure to attend follow-up studies
Interventions Treatment: Padma 28 (380 mg) two capsules twice a day
Control: Placebo (Lactose 400 mg) two capsules twice a day
Duration: 16 weeks (F/U: 4, 8, 12 weeks)
Outcomes Primary outcome: MWD with clinical relevance
Secondary outcomes:
1. Patient’s subjective evaluation
2. Upper arm BP
3. Serum lipids (total lipid, cholesterol, triglycerides, LDL) and platelet aggregation
Notes No intention-to-treat analysis
Participants received conventional angiography or Doppler ultrasound tonometry to
verify the clinical diagnosis
Participants were requested to stop vasoactive medications (washout period 2 weeks) but
were able to continue all other usual medications
Walking distances measurement method: treadmill set at 13º incline and a speed of 3.2
km/h
Adverse event reporting: Adverse events were investigated and none occurred
Additional patient information: location of the vascular obstruction - 70% femorodistal,
20% iliofemoral, 10% iliac
Manufacturer: Padma AG, Zurich
Reporting of significance level: “The significance limits for all tests were determined at
the 5% level (two-sided test)”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Reports: “The randomisation schedule was
compiled by the study coordinator in ac-
cordance with the Rumke and de Jong per-
mutation list”
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Smulski 1995 (Continued)
Allocation concealment (selection bias) Low risk Report: “He (2nd author) encoded sealed
packages and handed them to the examin-
ing and treating physician.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Reports: “The randomisation schedule was
kept confidential until the collection of
data was complete.”, “He did not disclose
randomisation schedule, particularly not to
patients nor to the examining and treating
physician.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Report: Full attrition data reported; 1/50
missing fromPadma 28 group due to newly
diagnosed bladder carcinoma; 6/50 miss-
ing from placebo group (all due to deteri-
oration in their overall condition). As all
withdrawals in placebo group were treat-
ment related, attrition bias classed as high
risk
Selective reporting (reporting bias) Low risk Reports: All expected outcomes reported
Other bias Low risk Authors report the distribution of pa-
tient characteristics was statistically ran-
dom among the control groups at time of
randomisation
ABI: ankle brachial index
BP: blood pressure
F/U: follow-up
IC: intermittent claudication
IQR: interquartile range
LDL: low density lipoprotein
m: metres
mg: milligram
MWD: maximum walking distance
PAOD: peripheral arterial occlusive disease
PFWD: pain-free walking distance
SD: standard deviation
SE: standard error
yrs: years
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Hurlimann 1978 Controlled clinical trial
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D A T A A N D A N A L Y S E S
Comparison 1. Padma 28 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in MWD 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Final value MWD 2 193 Mean Difference (IV, Fixed, 95% CI) 95.97 [79.07, 112.
88]
3 Adverse effects 4 231 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.42, 2.83]
4 Final value ankle brachial index 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Change in ankle brachial index 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 2. Padma 28 versus placebo sensitivity analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain-free walking distance 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Imputed final value data 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Ankle brachial index 2 92 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.10, 0.08]
2.1 Final value data 1 56 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.11, 0.09]
2.2 Imputed final value data 1 36 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.21, 0.17]
Analysis 1.1. Comparison 1 Padma 28 versus placebo, Outcome 1 Change in MWD.
Review: Padma 28 for intermittent claudication
Comparison: 1 Padma 28 versus placebo
Outcome: 1 Change in MWD
Study or subgroup Padma 28 Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Samochowiec 1987 55 75.7 (89.3) 45 -1.4 (7) 77.10 [ 53.41, 100.79 ]
-100 -50 0 50 100
Favours Placebo Favours Padma 28
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Analysis 1.2. Comparison 1 Padma 28 versus placebo, Outcome 2 Final value MWD.
Review: Padma 28 for intermittent claudication
Comparison: 1 Padma 28 versus placebo
Outcome: 2 Final value MWD
Study or subgroup Padma 28 Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Samochowiec 1987 55 156.2 (93.1) 45 66.6 (36.1) 39.9 % 89.60 [ 62.83, 116.37 ]
Smulski 1995 49 187.7 (69.6) 44 87.5 (33.1) 60.1 % 100.20 [ 78.40, 122.00 ]
Total (95% CI) 104 89 100.0 % 95.97 [ 79.07, 112.88 ]
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 11.13 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours Placebo Favours Padma 28
Analysis 1.3. Comparison 1 Padma 28 versus placebo, Outcome 3 Adverse effects.
Review: Padma 28 for intermittent claudication
Comparison: 1 Padma 28 versus placebo
Outcome: 3 Adverse effects
Study or subgroup Padma 28 Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mehlsen 1995 0/18 0/18 Not estimable
Sallon 1998 5/30 3/29 31.3 % 1.73 [ 0.37, 8.03 ]
Schra¨der 1985 8/23 8/20 68.7 % 0.80 [ 0.23, 2.76 ]
Smulski 1995 0/49 0/44 Not estimable
Total (95% CI) 120 111 100.0 % 1.09 [ 0.42, 2.83 ]
Total events: 13 (Padma 28), 11 (Placebo)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Padma 28 Favours Placebo
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Analysis 1.4. Comparison 1 Padma 28 versus placebo, Outcome 4 Final value ankle brachial index.
Review: Padma 28 for intermittent claudication
Comparison: 1 Padma 28 versus placebo
Outcome: 4 Final value ankle brachial index
Study or subgroup Padma 28 Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sallon 1998 31 0.72 (0.17) 25 0.73 (0.2) -0.01 [ -0.11, 0.09 ]
-0.5 -0.25 0 0.25 0.5
Favours Placebo Favours Padma 28
Analysis 1.5. Comparison 1 Padma 28 versus placebo, Outcome 5 Change in ankle brachial index.
Review: Padma 28 for intermittent claudication
Comparison: 1 Padma 28 versus placebo
Outcome: 5 Change in ankle brachial index
Study or subgroup Padma 28 Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sallon 1998 31 -0.02 (0.11) 25 -0.01 (0.1) -0.01 [ -0.07, 0.05 ]
-0.2 -0.1 0 0.1 0.2
Favours Placebo Favours Padma 28
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Analysis 2.1. Comparison 2 Padma 28 versus placebo sensitivity analysis, Outcome 1 Pain-free walking
distance.
Review: Padma 28 for intermittent claudication
Comparison: 2 Padma 28 versus placebo sensitivity analysis
Outcome: 1 Pain-free walking distance
Study or subgroup Padma 28 Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Imputed final value data
Mehlsen 1995 18 86 (104) 18 71 (67) 15.00 [ -42.15, 72.15 ]
-100 -50 0 50 100
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Analysis 2.2. Comparison 2 Padma 28 versus placebo sensitivity analysis, Outcome 2 Ankle brachial index.
Review: Padma 28 for intermittent claudication
Comparison: 2 Padma 28 versus placebo sensitivity analysis
Outcome: 2 Ankle brachial index
Study or subgroup Padma 28 Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Final value data
Sallon 1998 31 0.72 (0.17) 25 0.73 (0.2) 79.3 % -0.01 [ -0.11, 0.09 ]
Subtotal (95% CI) 31 25 79.3 % -0.01 [ -0.11, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
2 Imputed final value data
Mehlsen 1995 18 0.59 (0.3) 18 0.61 (0.29) 20.7 % -0.02 [ -0.21, 0.17 ]
Subtotal (95% CI) 18 18 20.7 % -0.02 [ -0.21, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 49 43 100.0 % -0.01 [ -0.10, 0.08 ]
-1 -0.5 0 0.5 1
Favours Placebo Favours Padma 28
(Continued . . . )
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(. . . Continued)
Study or subgroup Padma 28 Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
-1 -0.5 0 0.5 1
Favours Placebo Favours Padma 28
A D D I T I O N A L T A B L E S
Table 1. Reasons for withdrawal
Mehlsen 1995 Sallon 1998 Samochowiec 1987 Schräder 1985 Smulski 1995
Padma 28 4/40 withdrawals:
3 insufficient time to
participate
1 non-attendance
6/37 withdrawals:
3 gastrointestinal dis-
comfort
1 poor compliance
1 failure to improve
1 death due toMI and
CVA
0/50 withdrawals 4/27 withdrawals:
2 cardiac concerns
1 toe amputation
1 back pain
1/50 withdrawals:
1 bladder carcinoma
Placebo 7/35 withdrawals:
1 gastrointestinal dis-
comfort
3 no improvement
3 worsening condi-
tions
0/50 withdrawals 6/26 participants:
2 cardiac concerns
1 dyspnoea
1 stroke
1 lumbago
1 other (no ’steady
state’ achieved after 4
weeks)
6/50 withdrawals:
6 deterioration in over-
all condition
CVA: cerebrovascular accident
MI: myocardial infarction
Table 2. Pain-free walking distance
Study Group Median base-
line PFWD
(m)
IQR Median final
PFWD (m)
IQR Change in median
PFWD (m)
P*
Mehlsen 1995 Padma 28 52 20 - 106 86 24 - 164 34 < 0.01
34Padma 28 for intermittent claudication (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Pain-free walking distance (Continued)
Placebo 70 29 - 140 71 29 - 120 1 NS
Schräder 1985 Padma 28 65 131 66 0.002
Placebo 65 95 30 0.01
*P value refers to difference between baseline and follow-up PFWD values
IQR: interquartile range
m: metres
NS: not significant
PFWD: pain-free walking distance
Table 3. Maximum walking distance
Study Group Mean base-
line MWD
(m)
SD Mean final
MWD (m)
SD Change in
mean MWD
(m)
SD P*
Samo-
chowiec
1987
Padma 28 80.6 38.8 156.2 93.1 75.7 89.3 < 0.001
Placebo 68.1 37.0 66.6 36.1 -1.4 7.0 > 0.1
Smulski
1995
Padma 28 87.5 30.0 187.7 69.6 100.2 < 0.001
Placebo 75.0 27.8 87.5 33.1 12.5 NS
Study Group Median
baseline
MWD (m)
IQR Median final
MWD (m)
IQR Change in
median
MWD (m)
P
Mehlsen
1995
Padma 28 115 72 - 218 227 73 - > 1000 112 < 0.001
Placebo 125 59 - 285 132 64 - 336 7 NS
Schräder
1985
Padma 28 127 251 124 < 0.01
Placebo 141 168 27 NS
*P value refers to difference between baseline and follow up MWD values
IQR: interquartile range
m: metres
MWD: maximum walking distance
SD: standard deviation
NS: not significant
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Table 4. Adverse effects
Mehlsen 1995 Sallon 1998 Schräder 1985 Smulski 1995
Padma 28 0 reported 5 participants:
3 gastrointestinal discomfort
2 tiredness
8 in Padma 28 and 8 in placebo:
stomach pain, gastrointestinal
symptoms,
and skin eruption
0 reported
Placebo 0 reported 3 participants:
1 gastrointestinal discomfort
2 tiredness
0 reported
Table 5. Ankle brachial index
Study Group Mean base-
line ABI
SD Mean final
ABI
SD Change in
mean ABI
SD P*
Sallon 1998 Padma 28 0.73 0.11 0.72 0.17 -0.02 0.11 NS
Placebo 0.74 0.15 0.73 0.2 -0.01 0.1 NS
Study Group Median
baseline
ABI
IQR Median
final ABI
IQR Change in
median ABI
P*
Mehlsen
1995
Padma 28 0.62 0.42 - 0.83 0.59 0.43 - 0.82 -0.03 NS
Placebo 0.59 0.39 - 0.77 0.61 0.39 - 0.78 0.02 NS
*P value refers to difference between baseline ABI and final ABI values
ABI: ankle brachial index
IQR: interquartile range
NS: not significant
SD: standard deviation
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A P P E N D I C E S
Appendix 1. PADMA 28 ingredients
PADMA AG, Wiesenstrasse 5, 8603 Schwerzenbach, Switzerland. One capsule / one tablet contains: Columbine 15 mg, valerian root
10 mg, d-camphor 4 mg, aconite 1 mg, lettuce leaf 6 mg, clove 12 mg, golden cinquefoil 15 mg, kaempferia galanga rhizome 10 mg,
costus root 40mg, Iceland moss 40 mg, cardamom fruit 30 mg, Bengal quince 20 mg, myrobalan fruit 30 mg, calcium sulphate 20
mg, allspice 25 mg, neem fruit 35 mg, calendula flower 5 mg, red sandalwood 30 mg, heart-leaved sida 10 mg, ribwort plantain 15
mg, liquorice root 15 mg, knotgrass 15 mg and Excipients.
Appendix 2. CRS search strategy
Search run on Thu Sep 17 2015
#1 MESH DESCRIPTOR Arteriosclerosis 863
#2 MESH DESCRIPTOR Arteriolosclerosis EX-
PLODE ALL TREES
0
#3 MESH DESCRIPTOR Arteriosclerosis Oblit-
erans
69
#4 MESH DESCRIPTOR Atherosclerosis 493
#5 MESHDESCRIPTOR Arterial Occlusive Dis-
eases
695
#6 MESHDESCRIPTOR Intermittent Claudica-
tion
669
#7 MESH DESCRIPTOR Ischemia 720
#8 MESH DESCRIPTOR Peripheral Vascular
Diseases EXPLODE ALL TREES
2080
#9 (atherosclero* or arteriosclero* or PVD or
PAOD or PAD ):TI,AB,KY
7943
#10 ((arter* or vascular or vein* or veno* or pe-
ripher*) near3 (occlus* or reocclus* or re-occlus*
or steno* or restenos* or obstruct* or lesio* or
block* or harden* or stiffen* or obliter*) ):TI,
AB,KY
6730
#11 (peripheral near3 dis*):TI,AB,KY 2888
#12 (claudic* or IC):TI,AB,KY 2626
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(Continued)
#13 (isch* or CLI):TI,AB,KY 20212
#14 arteriopathic or leriche*:TI,AB,KY 54
#15 dysvascular*:TI,AB,KY 9
#16 (leg near3 (occlus* or reocclus* or re-occlus*
or steno* or restenos* or obstruct* or lesio* or
block* or harden* or stiffen* or obliter*) ):TI,
AB,KY
78
#17 (limb near3 (occlus* or reocclus* or re-occlus*
or steno* or restenos* or obstruct* or lesio* or
block* or harden* or stiffen* or obliter*) ):TI,
AB,KY
117
#18 ((lower near3 extrem*) near3 (occlus* or reoc-
clus* or re-occlus* or steno* or restenos* or ob-
struct* or lesio* or block* or harden* or stiffen*
or obliter*) ):TI,AB,KY
71
#19 MESH DESCRIPTOR Leg EXPLODE ALL
TREES WITH QUALIFIERS BS
1062
#20 MESH DESCRIPTOR Iliac Artery 135
#21 MESH DESCRIPTOR Popliteal Artery 248
#22 MESH DESCRIPTOR Femoral Artery 725
#23 MESH DESCRIPTOR Tibial Arteries 30
#24 (((femor* or iliac or popliteal or fempop* or
crural or poplite* or infrapopliteal or inguinal
or femdist* or inguinal or infrainquinal or tib-
ial) near3 (occlus* or reocclus* or re-occlus*
or steno* or restenos* or obstruct* or lesio* or
block* or harden* or stiffen* or obliter*) )):TI,
AB,KY
929
#25 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #
7 OR #8 OR #9 OR #10 OR #11 OR #12 OR
#13 OR #14 OR #15 OR #16 OR #17 OR #
18 OR #19 OR #20 OR #21 OR #22 OR #23
or #24
37825
#26 MESHDESCRIPTORMedicine, Tibetan Tra-
ditional EXPLODE ALL TREES
3
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(Continued)
#27 Tibetan:TI,AB,KY 46
#28 Padma*:TI,AB,KY 22
#29 #26 OR #27 OR #28 60
#30 #25 AND #29 14
#31 * NOT SR-PVD:CC AND 30/04/2013 TO
30/09/2015:DL
200160
#32 #30 AND #31 0
WH A T ’ S N E W
Last assessed as up-to-date: 17 September 2015.
Date Event Description
17 May 2016 Review declared as stable This Cochrane review has beenmarked stable and will only be updated when new studies
are identified
H I S T O R Y
Protocol first published: Issue 4, 2008
Review first published: Issue 7, 2013
Date Event Description
20 September 2015 New citation required but conclusions have not
changed
Searches rerun, no new trials identified. Review up-
dated according to currentCochrane guidelines. ’Sum-
mary of findings’ table added. No change in conclu-
sions
20 September 2015 New search has been performed Searches rerun, no new trials identified
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C O N T R I B U T I O N S O F A U T H O R S
JM: selected trials, assessed trial methodology, extracted data, and wrote the text of the review
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
According to updated Cochrane guidance, a GRADE ’Summary of findings’ table was added in this review using theCochraneHandbook
for Systematic Reviews of Interventions guidelines (Higgins 2011) and GRADE recommendations (Atkins 2004).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Walking; Intermittent Claudication [∗drug therapy]; Placebo Effect; Plant Extracts [adverse effects; ∗therapeutic use]; Randomized
Controlled Trials as Topic; Time Factors
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MeSH check words
Humans
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